Look At (NYSE: VNRX) Before You Do Anything Else This Morning Because It Is Still Trending Below $1

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored VolitionRx Limited (NYSE: VNRX) Just Landed On Our Watchlist This Morning — Thursday, July 30, 2026 Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get VNRX On Your Radar While It’s Still Early… July 30, 2026 Dear Reader, You have about 90 minutes before the open. Spend a few of them here. VolitionRx Limited (NYSE American: VNRX) is topping our watchlist this morning—Thursday, July 30, 2026. Here is the reason that matters most. Sysmex Corporation has built diagnostics equipment since 1968. Its analyzers run in hospital labs across more than 190 countries and regions. On June 17, 2026, it signed a collaboration agreement with Volition, a company carrying a market value near $7Mn. Read that again. A global manufacturer signed with a $7Mn company. Agreements rarely run that way. Sysmex has its pick of partners. It committed engineering time here for one reason: the Nu.Q NETs H3.1 assay had already been transferred onto the Sysmex platform successfully. Volition's whole plan is to license its assays to partners who already own the analyzers and the hospital relationships. Before June 17, that plan lived on a slide. It is now signed with one of the largest in vitro diagnostics manufacturers in the world. But keep in mind, VNRX has less than 7M shares listed as available to the public right now. When companies have small floats like this, the potential exists for big swings if demand starts to change. At the same time, VNRX appears to be flying under the radar while it’s currently trending below $1, according to Barchart. That has pushed the near-term momentum readings into rare territory. Barchart currently shows the Relative Strength Index on VNRX at 15.49 on a 9-day basis, 21.92 on 14-day, and 26.61 on 20-day. Anything under 30 is what most technical readers would call oversold territory, a condition some frameworks associate with the setup for a potential trend reversal. Several analysts have taken notice. Maxim Group analyst Michael Okunewitch reiterated a bullish rating on VNRX on July 24 with a $4 target. And according to TipRanks, Justin Walsh at Jones raised his target on VNRX from $3 to $24 in May, a level that sits well above its recent sub-$1 range. Revenue has also begun moving in the right direction. Volition reported first-quarter 2026 revenue of approximately $1Mn, representing a 300% increase from the same period last year. And Sysmex was not the only signed development to land on this name over the past few weeks. The July news added a second clinical leg. On July 7, 2026, Volition released real-world data showing its Nu.Q Cancer assay carried prognostic value in newly diagnosed lung cancer patients, work produced alongside clinicians at Hospices Civils de Lyon. Clinical certification of the test at that hospital system is complete, and the company is preparing a reimbursement submission in France with routine clinical use targeted before year end. Before we walk through the recent milestones, here is the foundation readers need first. Company Overview VolitionRx Limited is a multi-national epigenetics company developing blood-based tests for the detection and monitoring of cancer and of diseases associated with NETosis, including sepsis. Research and development is centered in Belgium, with an innovation laboratory and office in the United States and an office in London. The company is headquartered in Henderson, Nevada and employs roughly 67 people. Everything the company sells is built on a single proprietary platform called Nucleosomics, which measures nucleosomes and their epigenetic modifications circulating in blood. From that one core, Volition has built four commercial pillars, each addressing a different clinical problem without requiring four separate research programs. Nu.Q Vet is the furthest along commercially. The canine cancer test is already available in more than 20 countries. A feline version aimed at lymphoma, the most common cancer in cats, has been submitted for peer review after detecting 86% of feline lymphomas at 97% specificity. Publication is expected to unlock a $5Mn contractual milestone payment, and management believes a feline test could roughly double its addressable market in companion animal health. Nu.Q NETs is CE-marked and clinically available across Europe, addressing an estimated $3.8Bn market. Nu.Q Cancer is moving toward routine clinical use in lung cancer in France. Capture-Seq is the earliest-stage and by far the largest pillar, a liquid biopsy method the company estimates addresses roughly $23Bn on an annualized basis. Revenue today comes from assay sales, research services through Nu.Q Discover, contractual milestone payments, and non-dilutive funding from Walloon Region agencies in Belgium. The licensing model is where management expects the step change: upfront payments, milestones, and royalties from large diagnostics groups. The company has confirmed active discussions with more than a dozen of the world’s leading diagnostics and liquid biopsy companies, several already at the technical evaluation stage. Market Sector Liquid biopsy is one of the few corners of diagnostics where the clinical need and the reimbursement path are moving at the same time. The economics are simple enough to state in a sentence: a blood draw that identifies disease earlier costs a fraction of the imaging, biopsy, and late-stage treatment it displaces. What has held the field back is not the science but the cost and complexity of the assays themselves. Sequencing-based approaches remain expensive enough that broad screening is difficult to justify outside high-risk groups. Volition’s position inside that sector is unusual in two respects. The first is that it is platform-based rather than indication-based. Most diagnostics companies of this size are built around one test for one disease, which means one regulatory path and one point of failure. Volition’s nucleosome chemistry supports cancer detection, sepsis triage, chronic inflammatory disease monitoring, and veterinary oncology from the same underlying science. That gives VNRX several independent paths forward on a single research budget. The second is that it is deliberately capital-light on the commercial side. The company estimates combined addressable markets above $27Bn across its pillars. The sepsis side deserves separate attention. Published estimates put global sepsis cases near 166M annually, with all-cause sepsis-related deaths representing 31.5% of total global deaths in 2021. Volition’s Nu.Q NETs assay is already included in DETECSEPS, a government-backed program in France valued at roughly $7.3Mn and scheduled to begin in the third quarter of 2026. The Run Of News Behind Our Coverage On (VNRX) July 7, 2026 – Volition released clinical data showing the prognostic value of its Nu.Q Cancer assay in newly diagnosed lung cancer patients, produced with researchers at Hospices Civils de Lyon, France’s second largest university hospital system. Clinical certification of the test at HCL is complete and a reimbursement submission in France is being prepared. June 17, 2026 – The company announced its collaboration with Sysmex (TYO: 6869) to optimize the Nu.Q NETs H3.1 assay on the Sysmex platform, following successful transfer of the assay onto that system. June 3, 2026 – Volition filed a new patent application covering use of its Nu.Q NETs test for triage and treatment monitoring in outbreak settings, and stated it is seeking strategic partners to deploy the platform in affected regions. May 27, 2026 – A consolidated corporate update detailed 300% first quarter revenue growth, progress toward the $5Mn veterinary milestone, inclusion of Nu.Q NETs in the DETECSEPS program, and active licensing discussions with more than a dozen global diagnostics leaders. May 6, 2026 – The company submitted for peer review a clinical manuscript reporting the accuracy of its Nu.Q Vet feline prototype assay in detecting lymphoma in cats, publication of which is expected to unlock a $5Mn contractual milestone payment. April 29, 2026 – Volition reported successful detection of nucleosomes in capillary blood from critically ill sepsis patients using a lateral flow prototype, a finger-prick format that could extend testing to the bedside, the emergency room, and eventually the home. 7 Reasons Why VNRX Is Topping Our Watchlist This Morning—Thursday, July 30, 2026… 1. Global Validation: VNRX secured a collaboration with Sysmex, one of the world's largest diagnostics manufacturers, following the successful transfer of its Nu.Q NETs H3.1 assay onto the Sysmex platform. 2. Small Float: With fewer than 7M shares listed as available to the public, VNRX’s small float could have the potential to witness big swings if demand begins to shift. 3. Recent Developments: VNRX has delivered a steady stream of developments in recent months, including a Sysmex collaboration, new clinical data, patent activity, and continued commercial progress. 4. Analyst Coverage: VNRX continues to receive bullish analyst coverage, including a $4 target from Maxim Group and a $24 target from Jones analyst Justin Walsh, according to TipRanks. 5. Revenue Growth: VNRX reported first-quarter 2026 revenue of approximately $1M, representing a 300% increase from the same period last year. 6. Platform Diversity: VNRX has built four commercial programs from its proprietary Nucleosomics platform, spanning cancer, sepsis, veterinary diagnostics, and liquid biopsy applications. 7. Clinical Momentum: VNRX recently reported new lung cancer data, completed clinical certification at a major French hospital system, and is preparing a reimbursement submission in France with routine clinical use targeted before year end. Get VNRX On Your Radar While It’s Still Early… Step back from the daily noise, and the picture on VNRX is straightforward. With fewer than 7M shares in its float, a market value under $10M, a new Sysmex collaboration, triple-digit revenue growth, and a potential $5M contractual payment tied to a manuscript already under peer review, VNRX has several developments worth watching. Nothing is guaranteed. Peer review can take time, licensing discussions may stall, and the company’s financial position should be reviewed directly in its filings. Still, whether your focus is emerging healthcare names, small-float setups, or licensing-driven companies, VNRX deserves a place on the screen. We’re already watching VNRX this morning. Take a look while it’s still early, and keep an eye out for my next update. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and SNT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between TD Media LLC and Goldwyn Media LLC, TD Media LLC has been hired for a period beginning on 07/29/2026 and ending on 07/30/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, Goldwyn Media LLC has paid TD Media LLC fifty thousand USD (“Funds”). To date, including under the previously described agreement, TD Media LLC has been paid five hundred fifteen thousand five hundred USD (“Funds”). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/vnrx-TK2Ns/#details

TD Media LLC | 5826 New Territory Blvd., Unit #2144, Sugar Land, TX 77479 Unsubscribe Update Profile | About our service provider Sent by jeff@stocknewstrends.com

PayPal’s earnings, strong cash flow, and reported takeover inter...  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

July 30, 2026   |   Read online PayPal Q2 Earnings: Two Markets, Two Valuations PayPal’s earnings, strong cash flow, and reported takeover interest are changing the investment story. Here’s why it’s back on my watchlist. Trump's lighting the fuse under gold… you're still waiting (ad) PayPal Holdings Inc (NASDAQ: PYPL)second-quarter earnings arrived with adjusted EPS of $1.38 and total revenue of $8.68 billion, management raised its full-year outlook, and the company continued talking up its transformation strategy. Table of Contents Cashflow Makes A Stronger Case Growth Needs Better Execution Trend Finds New Direction Watch, Don’t Change Three months ago, I argued Q1 “respectable” results weren’t enough to change my mind because the business was stabilizing faster than it was accelerating, and the market seemed to agree.  This quarter, something changed. Not because of the earnings. But because PayPal reportedly received an offer worth more than $53 billion and a $60.50-per-share takeover approach from a consortium led by Advent International and Stripe before rejecting it in favor of remaining independent. Suddenly, this isn’t just a debate between management and public shareholders over what PayPal is worth. There are sophisticated buyers willing to put real money behind a different answer. The earnings will tell us whether management’s transformation is finally becoming visible in the numbers. The reported bid tells us someone already believes it is. Elon's New Currency (BUY NOW) (ad) It's bigger than SpaceX… xAI… or anything Tesla is working on. And it could launch a $480 trillion disruption, thanks to a massive rollout that's already begun all over America. Because Elon's new move targets the biggest market of them all… He's now launching a CURRENCY system.  Here's exactly what to buy to profit. Cashflow Makes A Stronger Case If Stripe and Advent did spend months evaluating PayPal, they weren’t buying a turnaround story. They were buying a cash-generating business they believed could become more valuable than the public market was willing to recognize. This quarter gives them a case to make. Total Payment Volume rose 10% year over year to $443.5 billion, transaction margin dollars increased 7% to $3.8 billion, and PayPal generated $1.8 billion in free cash flow during the quarter. The company also repurchased roughly $1.5 billion of its own shares while raising full-year guidance for both non-GAAP earnings per share and transaction margin dollar growth. It’s difficult to argue the business is fading when it’s still throwing off billions in cash and funding its own transformation in this fashion. But there’s another side to the ledger. Operating margin narrowed, transaction margin slipped to 44.9% from 46.4% a year ago, and profitability still isn’t expanding at the same pace as payment volume. That’s the same tension I pointed out after Q1. More payments alone don’t automatically create a more valuable business. The market wants proof that PayPal’s transformation can lift the economics of every transaction, not simply process more of them Growth Needs Better Execution One reason I wasn’t willing to own PayPal Holdings after last quarter was that the company’s transformation story remained largely theoretical. Management kept talking about branded checkout, Venmo, Braintree, and new commerce initiatives. However, the financial statements still looked like those of a mature payments company fighting for incremental growth rather than creating a new earnings engine.  This quarter doesn’t completely erase that concern, but it does give the strategy more credibility. Branded Checkout returned to healthier growth, Venmo continued expanding beyond peer-to-peer payments, and management is putting more emphasis on merchant services, advertising, in-store payments and AI-powered commerce. None of those businesses will transform PayPal overnight. Together, however, they point toward something larger: generating more revenue from each merchant and customer already inside its network instead of relying primarily on processing more payment volume. That’s why you need to pay attention to the reported takeover. See, Stripe isn’t trying to buy PayPal because it processes payments. Stripe already does that exceptionally well. If the reports are accurate, the attraction is more likely the combination of PayPal’s global consumer network, merchant relationships, Venmo ecosystem and cash-generation potential. Those are strategic assets that can become more valuable under the right execution… and exactly the kind of assets public markets often undervalue while focusing on quarterly growth rates. Trend Finds New Direction In the last quarter, I said PayPal’s chart looked “supported, not sponsored.” Buyers were willing to step in after earnings, but not with enough conviction to change the longer-term trend.  Well, that is harder to defend now. PayPal has broken the downtrend that defined much of the past year, reclaimed its 20-day and 50-day moving averages, and is now trading comfortably above both while approaching its 200-day moving average. More importantly, the stock is making higher highs and higher lows instead of simply bouncing after earnings. That’s the kind of price structure that suggests institutions are accumulating positions rather than merely covering shorts. There’s another detail that’s difficult to ignore. The stock is trading around the same level as the reported $60.50-per-share takeover approach. Whether a deal eventually materializes is almost beside the point. The reported bid has introduced a second reference point for valuation, one that’s no longer coming exclusively from public markets. From the way I see it, investors are becoming more willing to give management the benefit of the doubt. It's one of Trump's biggest holdings. Do you own it? (ad) President Trump owns up to $5 million in shares of this AI company (not Nvidia or SpaceX). He's strongly endorsed its leadership and products. And he just awarded it with a nearly $10 billion Pentagon contract. No wonder one legendary fund manager says it could become the cornerstone of your retirement. Click here for its name and ticker. Watch, Don’t Change Three months ago, I argued that PayPal wasn’t a broken business, but one that hadn’t done enough to earn investors’ conviction. I don’t think this quarter completely overturns that view. That said, one thing has changed. PayPal is no longer just being judged by public shareholders. Reports that Stripe and Advent explored a roughly $60.50-per-share bid introduced a second opinion, and one from buyers with every incentive to value the business correctly. Private equity doesn’t pay premiums for nostalgia, and strategic buyers don’t spend months evaluating companies they believe are in terminal decline. I’m still not ready to own PayPal today. But unlike last quarter, I’m also no longer comfortable dismissing it. If management can prove that its transformation translates into sustained margin expansion and stronger profitability, I’d be willing to revisit my thesis. For the first time in a while, PayPal has moved off my “avoid” list and onto my watchlist More Stories for You PayPal Q2 Earnings: Two Markets, Two Valuations [Recommended] 🎯 MAKE THIS 1 TRADE AT 2:59 PM ON FRIDAY AFTERNOON (From our friends at Millionaire Publishing) Morgan Stanley Says These 4 Quality Stocks Could Be Smart Buys Right Now   Update your email preferences or unsubscribe here © 2026 The Alpha Angle 33 Southeast 4th Street Boca Raton, FL 33432, United States Terms of Service

Coverage On (Nasdaq: IMNN) Kicks Off This Morning With Q2 Earnings Days Away And Two Positive Clinical Readouts Behind It

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored IMUNON, Inc. (Nasdaq: IMNN) Just Landed On Paul Prescott's Watchlist This Morning—Thursday, July 30, 2026 Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Get IMNN On Your Radar While It’s Still Early… July 30, 2026 Dear Reader, If you missed our first update last night, here is the setup on IMUNON, Inc. (Nasdaq: IMNN) you need before the bell rings. Street Ideas is always looking for late-stage clinical companies where the story behind the setup looks like it could accelerate, and IMNN is one of them right now. Two positive clinical readouts in just three days is the kind of momentum most late-stage clinical companies do not produce in an entire quarter. IMNN delivered exactly that between July 21 and July 23, and it is hosting its Q2 2026 earnings call next Tuesday, August 4, 2026 at 11:00 a.m. EDT. That is three events inside a two-week window, which is a potential catalyst cluster worth keeping an eye on. What makes it stand out from the Street Ideas desk is the fact that IMNN also carries a tight share structure, an FDA-aligned Phase 3 protocol, and a confirmed path toward a Biologics License Application filing. The clinical readouts themselves reinforce the setup. On July 21, IMNN reported fresh preliminary data from its Phase 2 residual disease trial led by researchers at MD Anderson in partnership with Break Through Cancer. Two days later, on July 23, IMNN was invited to present additional clinical data at the inaugural AACR D3 conference in Boston. Both readouts landed inside the same week, and both fit the same narrative management has been building toward the Phase 3 primary analysis. These are only some of the reasons IMNN is topping the Street Ideas watchlist this morning, Thursday, July 30, 2026. But keep in mind, IMNN has less than 4M shares listed as available to the public right now. When companies have small public floats like this, the potential exists for big moves. Analyst coverage adds another layer to the story. IMNN has a Strong Bullish consensus with an average 12-month target of $17.00, while published targets include $12 from Alliance Global Partners, $10 from Maxim Group, $25 from H.C. Wainwright, and a $25 valuation from Zacks Research. With clinical data continuing to strengthen the case and several key milestones now converging, IMNN could be entering one of the most important stretches in its recent history. Before we break down each of those developments, it is worth taking a closer look at the company and the science driving its lead program. Inside (IMNN)'s Late-Stage Clinical Program IMUNON is a clinical-stage biotechnology company headquartered in Lawrenceville, New Jersey, developing DNA-based therapies for cancer and infectious disease. The lead program, IMNN-001, is a DNA-based therapy that instructs the body to produce a protein called IL-12 locally at the tumor site, activating the immune cells that hunt down cancer. IMNN-001 is delivered directly into the abdominal cavity once a week over a six-month course. That local, sustained approach is designed specifically to unlock IL-12's cancer-fighting potential without the toxicity that limited earlier attempts. The Company runs two platforms. TheraPlas supports the lead oncology program, while PlaCCine is a DNA-based vaccine platform that produced IMNN-101, tested as a COVID-19 booster candidate in a first-in-human study. Stacy Lindborg, Ph.D. leads the executive team as President and Chief Executive Officer, with Douglas V. Faller, M.D., Ph.D. serving as Chief Medical Officer and Josh Blacher serving as interim Chief Financial Officer. IMNN-001 has completed six ovarian cancer clinical trials to date and is now enrolling in the Phase 3 OVATION 3 registrational trial. The Broader Market Story Behind IMNN Street Ideas looks closely at the sector backdrop behind every late-stage clinical name we cover, and IMNN sits in one of the fastest-growing corners of healthcare. According to Precedence Research, the global cancer immunotherapy market sits at $136.39B in 2025, is projected to grow to $151.26B in 2026, and is expected to reach $367.63B by 2035 at a 10.42% compound annual growth rate. North America leads with a 42.14% revenue share, and hospitals continue to be the primary channel for immunotherapy delivery. Additional sizing from Grand View Research and Research and Markets point to the same directional story, with the tighter immuno-oncology therapeutics segment projected to reach $226.31B by 2030. That is the kind of tailwind Street Ideas wants behind a late-stage clinical program. Ovarian cancer, the target indication for IMNN-001, remains one of the most challenging gynecologic cancers to treat. More than 60% of women diagnosed die within five years, and most cases are not detected until the disease has already spread. Approximately 20,000 new cases are diagnosed in the U.S. each year and roughly 300,000 worldwide. The frontline standard of care has not seen a real advance in more than three decades. That is the gap IMNN-001 is being positioned to close as a first-in-class local immunotherapy with no direct competitor in the frontline setting, and it is the reason IMNN keeps landing on the Street Ideas radar. What Put IMNN On Our Radar Potential Catalyst Calendar That Keeps Building. July 21 residual disease readout, July 23 AACR D3 selection, and Q2 2026 earnings on August 4. Three events inside two weeks is unusual for a late-stage clinical name. Fresh Phase 2 Residual Disease Readout. The July 21, 2026 update from the MD Anderson-led trial showed less residual disease at follow-up surgery (44% versus 67%), better tumor DNA clearance (87.5% versus 62.5%), and 100% no evidence of disease versus 56% in the control arm. AACR D3 Selection. Two days later, IMNN-001 was showcased at the inaugural AACR D3 conference in Boston with a favorable immune-cell response and clean safety profile. Landmark Survival Data Behind It. The final March 25, 2026 Phase 2 OVATION 2 readout showed a 14.7-month median overall survival benefit, extending to 24.2 months with targeted maintenance therapy. Phase 3 Enrollment Ahead Of Plan. The June 23, 2026 iDMC vote confirmed the Phase 3 OVATION 3 study should continue without modification, with 27 of 80 target patients already dosed for Q1 2027. Published Analyst Targets Point Higher. IMNN carries a Strong Bullish analyst consensus with an average 12-month target of $17.00, a significant premium to recent share levels. Recent Milestones Behind IMNN July 23, 2026: IMNN-001 featured in poster at inaugural AACR D3 conference in Boston July 21, 2026: Fresh positive Phase 2 residual disease data reported from MD Anderson-led trial June 23, 2026: Independent DMC recommended Phase 3 OVATION 3 continue without modification June 4, 2026: Up to $10M cash financing announced, structured without warrants May 12, 2026: Q1 2026 results confirmed FDA alignment on Phase 3 protocol and BLA path March 25, 2026: Final Phase 2 OVATION 2 data showed 14.7-month median overall survival benefit July 30, 2025: First patient dosed in the Phase 3 OVATION 3 study Why IMNN Is Topping This Morning’s Watchlist —Thursday, July 30, 2026… 1. Analyst Coverage: Published coverage gives IMNN a Strong Bullish consensus and an average 12-month target of $17.00, with individual figures ranging from $10 to $25. 2. Very Small Float: With fewer than 4M shares listed as available to the public, IMNN’s small float could have the potential for big moves if demand begins to change. 3. Clinical Momentum: Two positive clinical readouts within three days have placed IMNN in the spotlight ahead of its next scheduled corporate update. 4. Survival Data: Final Phase 2 results showed IMNN-001 delivered a 14.7-month median overall survival benefit, rising to 24.2 months among women also receiving targeted maintenance therapy. 5. Phase 3 Progress: After an independent committee recommended continuing the study without modification, IMNN remained on track to reach 80 enrolled participants by Q1 2027. 6. Residual Disease: Fresh Phase 2 findings showed the IMNN-001 group had less residual disease, stronger tumor-DNA clearance, and a higher no-evidence-of-disease rate than the control arm. 7. FDA Pathway: With its Phase 3 protocol developed in agreement with the FDA and a confirmed path toward a Biologics License Application filing, IMNN has a defined regulatory framework for its lead program. Get IMNN On Your Radar While It’s Still Early… At Street Ideas, we look for companies where multiple developments begin coming together over a relatively short period of time. IMNN now checks several of those boxes with fresh clinical data, an upcoming earnings call, a defined regulatory path, and published analyst targets ranging from $10 to $25. We'll continue monitoring the story closely. Be sure to take another look at IMNN while it’s still early, and keep an eye on your inbox for my next update. Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter       Street-Ideas.com (“Street-Ideas” or “SI” ) is owned by 147 Media LLC, a single member limited liability company. Data is provided from third-party sources and SI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between 147 Media LLC and TD Media LLC, 147 Media LLC has been hired for a period beginning on 07/29/2026 and ending on 07/30/2026 to publicly disseminate information about (IMNN:US) via digital communications. Under this agreement, TD Media LLC has paid 147 Media LLC seven thousand five hundred USD (“Funds”). These Funds were part of the forty thousand USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither 147 Media LLC, TD Media LLC and their member own shares of (IMNN:US). Please see important disclosure information here: https://street-ideas.com/disclosure/imnn-gFvdv/#details

Street Ideas | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446 Unsubscribe Update Profile | About our service provider Sent by paul@street-ideas.com